Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Tameka D. Alestock"'
Autor:
Eun Young Kim, Casey Lynnette Overby, Braxton D. Mitchell, Kristin A. Maloney, Tom Fitzgerald, David Berman, Alan R. Shuldiner, Kathleen Palmer, Justin Chavez, Tameka D. Alestock, Reem Maged Sharaf
Publikováno v:
Journal of Personalized Medicine, Vol 5, Iss 3, Pp 264-279 (2015)
Journal of Personalized Medicine
Volume 5
Issue 3
Pages 264-279
Journal of Personalized Medicine
Volume 5
Issue 3
Pages 264-279
Background: Achieving high participation of communities representative of all sub-populations is needed in order to ensure broad applicability of biobank study findings. This study aimed to understand potentially mutable attitudes and opinions common
Autor:
Issam Hamadeh, Devon C. Nwaba, Nita A. Limdi, Amer Ardati, Josh F. Peterson, James M. Stevenson, Russell A. Wilke, Craig R. Lee, Kristin Weitzel, Tameka D. Alestock, Yan Gong, Kathleen Palmer, Joshua C. Denny, Stephen E. Kimmel, Almut G. Winterstein, Richard B. Horenstein, Mark R. Vesely, Todd C. Skaar, Caitrin W. McDonough, Supatat Chumnumwat, Dyson T. Wake, James H. Willig, Petr Starostik, Larisa H. Cavallari, Linda J. B. Jeng, Karen E. Weck, Chrisly Dillon, Michael J. Clare-Salzler, D. Max Smith, Jorge A. Alsip, Vindhya B. Sriramoju, Rolf P. Kreutz, Chintan V. Dave, Julie A. Johnson, William B. Hillegass, Victoria M. Pratt, Toni I. Pollin, R. David Anderson, Rhonda M. Cooper-DeHoff, Richard Y. Zhao, Yee Ming Lee, Shawn W. Robinson, Brigitta C. Brott, Deepak Voora, Tomasz Stys, Lindsay J. Hines, Alan R. Shuldiner, Ruth E. Pakyz, Mark D. Kelemen, Alison H. Quinn, Edith A. Nutescu, Shuko Harada, Lawrence Brown, David R. Nelson, Oyunbileg Magvanjav, Philip E. Empey, Lucius A. Howell, Amanda R. Elsey, May E. Montasser, Nicholas Varunok, James C. Coons, Amber L. Beitelshees, George A. Stouffer, Julio D. Duarte, Jamie Schub
Objectives This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous coronary intervention (PCI). Background CYP2C19 loss-of-function alleles impa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0020458ef2172864006eb4e8685cb22c
https://europepmc.org/articles/PMC5775044/
https://europepmc.org/articles/PMC5775044/
Autor:
Nicholas P. Ambulos, Richard Y. Zhao, Mark R. Vesely, Courtney O'Neill, Tameka D. Alestock, Miriam G. Blitzer, Patrick F. McArdle, Toni I. Pollin, Richard B. Horenstein, Ruth E. Pakyz, Lawrence Brown, Shaun Bhatty, Amber L. Beitelshees, Alan R. Shuldiner, Linda J. B. Jeng, Kathleen Palmer, Jamie Schub, Mark D. Kelemen, Shawn W. Robinson, Casey Lynnette Overby, Kristin A. Maloney
Publikováno v:
American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 166:76-84
Despite a substantial evidence base, implementation of pharmacogenetics into routine patient care has been slow due to a number of non-trivial practical barriers. We implemented a Personalized Anti-platelet Pharmacogenetics Program (PAP3) for cardiac